JP2008540674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540674A5 JP2008540674A5 JP2008512510A JP2008512510A JP2008540674A5 JP 2008540674 A5 JP2008540674 A5 JP 2008540674A5 JP 2008512510 A JP2008512510 A JP 2008512510A JP 2008512510 A JP2008512510 A JP 2008512510A JP 2008540674 A5 JP2008540674 A5 JP 2008540674A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- heterocycloalkyl
- compound according
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Z n - aryl Chemical group 0.000 claims 56
- 150000001875 compounds Chemical class 0.000 claims 37
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 230000010261 cell growth Effects 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 229910004013 NO 2 Inorganic materials 0.000 claims 2
- 206010029350 Neurotoxicity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229930195712 glutamate Natural products 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 2
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000007135 neurotoxicity Effects 0.000 claims 2
- 231100000228 neurotoxicity Toxicity 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010019842 Hepatomegaly Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 201000001705 nipple carcinoma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000006134 tongue cancer Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- KDJTYQSIVPDDJL-VFCFBJKWSA-N CCNc1cc(-c2c(Nc(cc3)cc(CC4)c3/C4=N/O)[n](ccnc3)c3n2)ccc1 Chemical compound CCNc1cc(-c2c(Nc(cc3)cc(CC4)c3/C4=N/O)[n](ccnc3)c3n2)ccc1 KDJTYQSIVPDDJL-VFCFBJKWSA-N 0.000 description 2
- PICUOMFLHXGSET-UHFFFAOYSA-N COC(c(cc1)ccc1-c1c(Nc(cc2CC3)ccc2C3=N)[n](ccnc2)c2n1)=O Chemical compound COC(c(cc1)ccc1-c1c(Nc(cc2CC3)ccc2C3=N)[n](ccnc2)c2n1)=O PICUOMFLHXGSET-UHFFFAOYSA-N 0.000 description 2
- HDEZGDFLLJMEFC-UHFFFAOYSA-N COc(nc1)ccc1-c1c(Nc(cc2)cc(CC3)c2C3=N)[n](ccnc2)c2n1 Chemical compound COc(nc1)ccc1-c1c(Nc(cc2)cc(CC3)c2C3=N)[n](ccnc2)c2n1 HDEZGDFLLJMEFC-UHFFFAOYSA-N 0.000 description 2
- WELWILILGUOEAT-UHFFFAOYSA-N C[n]1c(cccc2)c2c(-c2c(Nc(cc3)cc(CC4)c3C4=N)[n](ccnc3)c3n2)c1 Chemical compound C[n]1c(cccc2)c2c(-c2c(Nc(cc3)cc(CC4)c3C4=N)[n](ccnc3)c3n2)c1 WELWILILGUOEAT-UHFFFAOYSA-N 0.000 description 2
- OIBNEDDHWRHDFK-UHFFFAOYSA-N N=C(CC1)c(cc2)c1cc2Nc1c(-c2ccc(CO)cc2)nc2[n]1ccnc2 Chemical compound N=C(CC1)c(cc2)c1cc2Nc1c(-c2ccc(CO)cc2)nc2[n]1ccnc2 OIBNEDDHWRHDFK-UHFFFAOYSA-N 0.000 description 2
- WHSBBQWOOPDENF-HMMYKYKNSA-N C/N=C(\CC1)/c(cc2)c1cc2Nc1c(-c2ncc[s]2)nc2[n]1ccnc2 Chemical compound C/N=C(\CC1)/c(cc2)c1cc2Nc1c(-c2ncc[s]2)nc2[n]1ccnc2 WHSBBQWOOPDENF-HMMYKYKNSA-N 0.000 description 1
- WEQICZZABQJEQW-LFVJCYFKSA-N C[n]1c(-c2c(Nc(cc3)cc(CC4)c3/C4=N/O)[n](ccnc3)c3n2)ccc1 Chemical compound C[n]1c(-c2c(Nc(cc3)cc(CC4)c3/C4=N/O)[n](ccnc3)c3n2)ccc1 WEQICZZABQJEQW-LFVJCYFKSA-N 0.000 description 1
- RODVJIMEVXOBLV-UHFFFAOYSA-N C[n]1c(-c2c(Nc(cc3)cc(CC4)c3C4=N)[n](ccnc3)c3n2)ccc1 Chemical compound C[n]1c(-c2c(Nc(cc3)cc(CC4)c3C4=N)[n](ccnc3)c3n2)ccc1 RODVJIMEVXOBLV-UHFFFAOYSA-N 0.000 description 1
- RNZUABBGFCOFSB-UHFFFAOYSA-N N=C(CC1)c(cc2)c1cc2Nc1c(-c2ncc[s]2)nc2[n]1ccnc2 Chemical compound N=C(CC1)c(cc2)c1cc2Nc1c(-c2ncc[s]2)nc2[n]1ccnc2 RNZUABBGFCOFSB-UHFFFAOYSA-N 0.000 description 1
- AOWMREOLKQDOBF-NLRVBDNBSA-O Nc1cccc(-c2c(Nc(cc3)cc(CC4)c3/C4=N/[OH2+])[n](ccnc3)c3n2)c1 Chemical compound Nc1cccc(-c2c(Nc(cc3)cc(CC4)c3/C4=N/[OH2+])[n](ccnc3)c3n2)c1 AOWMREOLKQDOBF-NLRVBDNBSA-O 0.000 description 1
- 0 Nc1cccc(C2=C(Nc(cc3)cc(CC4)c3C4=NO)N(C=CN=C3)C3=*C2)c1 Chemical compound Nc1cccc(C2=C(Nc(cc3)cc(CC4)c3C4=NO)N(C=CN=C3)C3=*C2)c1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68317505P | 2005-05-20 | 2005-05-20 | |
| PCT/US2006/019280 WO2006125101A2 (en) | 2005-05-20 | 2006-05-18 | Raf inhibitor compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540674A JP2008540674A (ja) | 2008-11-20 |
| JP2008540674A5 true JP2008540674A5 (enExample) | 2009-06-18 |
Family
ID=37432152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512510A Pending JP2008540674A (ja) | 2005-05-20 | 2006-05-18 | Ｒａｆ阻害化合物およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7566716B2 (enExample) |
| EP (1) | EP1902056A2 (enExample) |
| JP (1) | JP2008540674A (enExample) |
| KR (1) | KR20080038278A (enExample) |
| CN (1) | CN101263142A (enExample) |
| AU (1) | AU2006247118A1 (enExample) |
| BR (1) | BRPI0610863A2 (enExample) |
| CA (1) | CA2609299A1 (enExample) |
| IL (1) | IL187509A0 (enExample) |
| MX (1) | MX2007014510A (enExample) |
| NO (1) | NO20076553L (enExample) |
| RU (1) | RU2007147382A (enExample) |
| WO (1) | WO2006125101A2 (enExample) |
| ZA (1) | ZA200710969B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006028862A1 (de) * | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| CN103739595A (zh) | 2006-10-02 | 2014-04-23 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| US20100298314A1 (en) * | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| EP2155747B1 (en) * | 2007-05-10 | 2012-10-24 | GE Healthcare Limited | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2062893A1 (en) * | 2007-10-18 | 2009-05-27 | Bayer Schering Pharma AG | Fused imidazoles for cancer treatment |
| MX2010001636A (es) * | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
| WO2009021990A1 (en) * | 2007-08-14 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Fused imidazoles for cancer treatment |
| WO2009111279A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| KR20100122505A (ko) * | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Ｒａｆ 저해물질 화합물 및 이들의 이용 방법 |
| US20110003809A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| EP2470532A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase |
| WO2011025938A2 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| JP2013503188A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Ｒａｆ阻害化合物およびその使用方法 |
| US20120157451A1 (en) | 2009-08-28 | 2012-06-21 | Genentech, Inc | Raf inhibitor compounds and methods of use thereof |
| WO2011025947A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| US20120214811A1 (en) | 2009-08-28 | 2012-08-23 | Ignacio Aliagas | Raf inhibitor compounds and methods of use thereof |
| KR101233082B1 (ko) | 2010-02-25 | 2013-02-14 | 주식회사 이큐스앤자루 | 신규한 이미다졸피라진 유도체 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스 치료용 약학적 조성물 |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| CN102406646B (zh) * | 2010-09-20 | 2015-09-09 | 北大方正集团有限公司 | 芳基脲衍生物用于制备治疗移植排斥药物的用途 |
| EP2661434A4 (en) | 2011-01-06 | 2014-07-09 | Beta Pharma Canada Inc | NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER |
| PT2694510E (pt) | 2011-04-07 | 2016-02-08 | Bayer Pharma AG | Imidazopiridazinas como inibidores da akt quinase |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP2797888B1 (en) | 2011-12-31 | 2016-06-08 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3394033B1 (en) | 2015-12-22 | 2020-11-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| MA47123A (fr) | 2016-12-22 | 2021-03-17 | Incyte Corp | Dérivés de benzooxazole en tant qu'mmunomodulateurs |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| PE20200005A1 (es) | 2016-12-22 | 2020-01-06 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1 |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| PL4212529T3 (pl) | 2018-03-30 | 2025-07-07 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| HRP20230306T1 (hr) | 2018-05-11 | 2023-05-12 | Incyte Corporation | Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori |
| MX2021006138A (es) * | 2018-11-26 | 2021-06-23 | Janssen Sciences Ireland Unlimited Co | Otros compuestos heteroaromaticos que tienen actividad contra el vrs. |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| IL291471B2 (en) | 2019-09-30 | 2025-04-01 | Incyte Corp | Pyrimido[3,2–D]pyrimidine compounds as immunomodulators |
| CR20220237A (es) | 2019-11-11 | 2022-08-05 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| AR124001A1 (es) | 2020-11-06 | 2023-02-01 | Incyte Corp | Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| CN116217416A (zh) * | 2022-12-31 | 2023-06-06 | 黄淮学院 | 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| CN1257169C (zh) | 1999-10-08 | 2006-05-24 | 格吕伦塔尔有限公司 | 双环咪唑－3－基－胺衍生物 |
| DE10019714A1 (de) | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| EP1343785A2 (de) | 2000-12-13 | 2003-09-17 | Basf Aktiengesellschaft | Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| DE10150172A1 (de) | 2001-10-11 | 2003-04-30 | Morphochem Ag | Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren |
| US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| WO2005120513A1 (en) | 2004-06-09 | 2005-12-22 | Oncalis Ag | Protein kinase inhibitors |
| DE102004044884A1 (de) | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen |
-
2006
- 2006-05-18 MX MX2007014510A patent/MX2007014510A/es not_active Application Discontinuation
- 2006-05-18 RU RU2007147382/04A patent/RU2007147382A/ru not_active Application Discontinuation
- 2006-05-18 CA CA002609299A patent/CA2609299A1/en not_active Abandoned
- 2006-05-18 WO PCT/US2006/019280 patent/WO2006125101A2/en not_active Ceased
- 2006-05-18 BR BRPI0610863-6A patent/BRPI0610863A2/pt not_active Application Discontinuation
- 2006-05-18 AU AU2006247118A patent/AU2006247118A1/en not_active Abandoned
- 2006-05-18 US US11/436,353 patent/US7566716B2/en not_active Expired - Fee Related
- 2006-05-18 KR KR1020077029801A patent/KR20080038278A/ko not_active Withdrawn
- 2006-05-18 JP JP2008512510A patent/JP2008540674A/ja active Pending
- 2006-05-18 CN CNA2006800266418A patent/CN101263142A/zh active Pending
- 2006-05-18 EP EP06784432A patent/EP1902056A2/en not_active Withdrawn
-
2007
- 2007-11-20 IL IL187509A patent/IL187509A0/en unknown
- 2007-12-18 ZA ZA200710969A patent/ZA200710969B/xx unknown
- 2007-12-19 NO NO20076553A patent/NO20076553L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540674A5 (enExample) | ||
| JP7447002B2 (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| RU2007147382A (ru) | Соединения, являющиеся ингибиторами raf, и способы их применения | |
| TWI740910B (zh) | 非環抗病毒劑 | |
| JP6078639B2 (ja) | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 | |
| KR102674466B1 (ko) | Pd-1/pd-l1 억제제 | |
| CN112592334B (zh) | 嘧啶衍生物作为激酶抑制剂 | |
| JP6873145B2 (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| TWI657083B (zh) | 用於抑制ｓｈｐ２活性之化合物及組合物 | |
| JP2021191770A (ja) | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 | |
| US8951993B2 (en) | Phosphorus containing compounds as protein kinase inhibitors | |
| JP2008530011A5 (enExample) | ||
| PT2727918T (pt) | Compostos e composições como inibidores de proteína quinase | |
| JP2021529172A (ja) | エクトヌクレオチダーゼ阻害剤及びその使用方法 | |
| JP2015505542A5 (enExample) | ||
| EP3503895A1 (en) | Antiviral prodrugs of tenofovir | |
| WO2011095045A1 (zh) | 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用 | |
| AU2016333505A1 (en) | New imidazo(4,5-B)pyridine derivatives as dual DYRK1/CLK1 inhibitors | |
| CN113563244B (zh) | 取代的氮杂五元环类化合物及其在药物中的应用 | |
| CN112442105A (zh) | 作为蛋白激酶抑制剂的新型嘧啶并[4,5-d]嘧啶-2-酮衍生物 | |
| CN104370825B (zh) | 作为激酶抑制剂的取代杂环化合物及其制备方法和用途 | |
| OA18645A (en) | New imidazo[4,5-b]pyridine derivatives as dual DYRK1/CLK1 inhibitors. |